MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Formule :C29H32ClN5O3Couleur et forme :SolidMasse moléculaire :534.05MAP855
CAS :<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Formule :C28H23ClF2N6O3Couleur et forme :SolidMasse moléculaire :564.97MBA-m1
CAS :<p>MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.</p>Formule :C27H21ClN2O2Couleur et forme :SolidMasse moléculaire :440.92ZCL279
CAS :<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Formule :C24H18N2O7S2Couleur et forme :SolidMasse moléculaire :510.539JD123
CAS :<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>Formule :C12H11N5S2Couleur et forme :SolidMasse moléculaire :289.379KRAS G12D inhibitor 28
CAS :<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Formule :C35H32Cl2FN5OCouleur et forme :SolidMasse moléculaire :628.57MLKL-IN-1
<p>MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.</p>Formule :C19H20N2O3Couleur et forme :SolidMasse moléculaire :324.37INCB159020
CAS :<p>INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.</p>Formule :C37H35ClFN7O2Couleur et forme :SolidMasse moléculaire :664.171GDC-6036-NH
CAS :<p>GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.</p>Formule :C26H30ClF4N7ODegré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :568.01KRAS inhibitor-13
CAS :<p>KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.</p>Formule :C25H19ClFN3O2SCouleur et forme :SolidMasse moléculaire :479.95HPK1-IN-42
CAS :<p>HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].</p>Formule :C26H30N6OSCouleur et forme :SolidMasse moléculaire :474.62AMG-548 hydrochloride
<p>AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.</p>Formule :C29H28ClN5OCouleur et forme :SolidMasse moléculaire :498.02SHR902275
CAS :<p>SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.</p>Formule :C26H23F3N4O4Couleur et forme :SolidMasse moléculaire :512.48ERK1/2 inhibitor 6
CAS :<p>ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.</p>Formule :C27H29ClFN7O5Couleur et forme :SolidMasse moléculaire :586.01RSK4-IN-1
CAS :<p>RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.</p>Formule :C19H20F2N4O3Couleur et forme :SolidMasse moléculaire :390.38HPK1-IN-3
<p>HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.</p>Formule :C23H22F4N6O2Couleur et forme :SolidMasse moléculaire :490.45SOS1-IN-9
<p>SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).</p>Formule :C22H28F3N5OCouleur et forme :SolidMasse moléculaire :435.49KRAS inhibitor-41
CAS :<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formule :C30H37FN10OSCouleur et forme :SolidMasse moléculaire :604.745KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Formule :C31H36ClFN6O2Couleur et forme :SolidMasse moléculaire :579.11Rho GTPase inhibitor 1
CAS :<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Formule :C18H16N2OCouleur et forme :SolidMasse moléculaire :276.33MEK4 inhibitor-2
CAS :<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Formule :C20H15FN4O3SCouleur et forme :SolidMasse moléculaire :410.42EBI-907
CAS :<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Formule :C23H21ClF2N4O3SCouleur et forme :SolidMasse moléculaire :506.95LSN3074753
CAS :<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Formule :C24H30FN5O2Couleur et forme :SolidMasse moléculaire :439.53L 739749
CAS :<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Formule :C24H41N3O6S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :531.73Fulzerasib
CAS :<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Formule :C32H30ClFN6O4Degré de pureté :98.04%Couleur et forme :SolidMasse moléculaire :617.07SOS1-IN-6
CAS :<p>SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).</p>Formule :C26H28F3N3O2Couleur et forme :SolidMasse moléculaire :471.51HPK1-IN-21
<p>HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.</p>Formule :C22H25ClFN5O2Couleur et forme :SolidMasse moléculaire :445.92Cot inhibitor-3
CAS :<p>Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.</p>Formule :C30H28N8OCouleur et forme :SolidMasse moléculaire :516.60MEK1/2-IN-2
<p>MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.</p>Formule :C28H22ClFN6OCouleur et forme :SolidMasse moléculaire :512.97BMS-214662
CAS :<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Formule :C25H23N5O2S2Degré de pureté :99.58% - 99.58%Couleur et forme :SolidMasse moléculaire :489.61HPK1-IN-16
CAS :<p>HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.</p>Formule :C28H27FN4OCouleur et forme :SolidMasse moléculaire :454.54HPK1-IN-31
<p>HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .</p>Formule :C30H33N7O3Couleur et forme :SolidMasse moléculaire :539.63AMG-548 dihydrochloride
<p>AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.</p>Formule :C29H29Cl2N5OCouleur et forme :SolidMasse moléculaire :534.48K-Ras-IN-4
CAS :<p>K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.</p>Formule :C31H28F4N6O3SCouleur et forme :SolidMasse moléculaire :640.65ERK2 IN-1
CAS :<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Formule :C36H34FN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :647.76HPK1-IN-30
CAS :<p>HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.</p>Formule :C25H23FN6Couleur et forme :SolidMasse moléculaire :426.49ATX inhibitor 26
CAS :<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Formule :C18H19Cl2N7O3Couleur et forme :SolidMasse moléculaire :452.30VVD-699
CAS :<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Formule :C25H30ClFN2O6S2Couleur et forme :SolidMasse moléculaire :573.097MCB-22-174
CAS :MCB-22-174 is a potent agonist of Piezo1 with an EC50 value of 6.28 µM. It activates Ca2+-related extracellular signal-regulated kinase and calcium-calmodulin (CaM)-dependent protein kinase II (CaMKII) pathways, and it promotes mesenchymal stem cell osteogenic differentiation, indicating its potential application in the study of disuse osteoporosis (OP).Formule :C16H14DCl2N5OS2Masse moléculaire :429.37SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Formule :C23H22ClN7O2Couleur et forme :SolidMasse moléculaire :463.92HPK1-IN-55
CAS :<p>HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.</p>Formule :C30H34N8O3Couleur et forme :SolidMasse moléculaire :554.643KRAS G12C inhibitor 50
CAS :<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Formule :C31H34N8O2Couleur et forme :SolidMasse moléculaire :550.65KRAS G12D inhibitor 3
CAS :<p>KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less than</p>Formule :C34H31ClF3N5O2Couleur et forme :SolidMasse moléculaire :634.09Sosimerasib
CAS :<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Formule :C36H39ClFN7O4Couleur et forme :SolidMasse moléculaire :688.191MRTX849 ethoxypropanoic acid
CAS :<p>MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.</p>Formule :C37H43ClFN7O5Couleur et forme :SolidMasse moléculaire :720.24KRAS G12D inhibitor 12
<p>KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)</p>Formule :C23H21ClFN5O3Couleur et forme :SolidMasse moléculaire :469.9ERK-IN-2
CAS :<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Formule :C16H18ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :347.80SML-10-70-1
CAS :<p>SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.</p>Formule :C25H42ClN7O13P2Couleur et forme :SolidMasse moléculaire :746.04Dorrigocin A
CAS :<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Formule :C27H41NO8Couleur et forme :SolidMasse moléculaire :507.616SOF-436
CAS :<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Formule :C15H13F2NO4S2Couleur et forme :SolidMasse moléculaire :373.395
